CAPR - Rasio rega marang prakiraan pendapatan Capricor Therapeutics Inc.

Can Capricor Therapeutics (CAPR) overcome biomanufacturing challenges and FDA risks? The forward EV/Revenue multiple provides the answer, and this metric is currently fixed at 163.30. Developments in exosome research and cellular treatment for dystrophy provide stability. Successful engagement between management and regulators, combined with preparations for commercialization, strengthen investor confidence in the company's assets.

Capricor - Prakiraan rega marang pendapatan CAPR (periode 04.07.2022 - 13.03.2026)

Ringkesan rincian data analitis capricor.com (CAPR)

- rega pasar lan target rega analis:

Bagan rega Capricor Therapeutics, Inc.|CAPR - Bagan rega target

- statistik kapitalisasi pasar:

Nilai pasar Capricor Therapeutics, Inc.|CAPR - Total Nilai Perusahaan

- indikator nilai buku ekuitas:

Nilai Buku saben Saham Capricor Therapeutics|CAPR - Nilai Buku Bisnis|Rasio Kapitalisasi marang Aset Bersih capricor.com|CAPR - Aset Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal Capricor Therapeutics|CAPR - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Capricor Therapeutics, Inc.|CAPR - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Capricor Therapeutics, Inc.|CAPR - Kewajiban jangka dawa|Utang jangka cendhak perusahaan Capricor Therapeutics|Rasio cepet capricor.com

- rincian asil keuangan lan kelipatan valuasi:

CAPR - Asil keuangan resik|Proyeksi bathi mangsa ngarep Capricor Therapeutics|CAPR - Koefisien rega marang bathi|Rega marang bathi mangsa ngarep Capricor Therapeutics, Inc.|CAPR - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Capricor Therapeutics, Inc.|CAPR - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Capricor Therapeutics|CAPR - Bathi saben saham sajroning taun lumaku|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan capricor.com|CAPR - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Capricor Therapeutics

- data pendapatan lan penerimaan dodolan:

CAPR - Pendapatan dodolan perusahaan|Prakiraan volume dodolan Capricor Therapeutics, Inc.|CAPR - Rega marang dodolan|Rasio rega marang prakiraan pendapatan Capricor Therapeutics, Inc.

Analisis fundamental perusahaan:CAPR (Capricor)

The lack of a commercial base at Capricor Therapeutics (CAPR) leaves the company dependent on FDA approval and clinical trial results. By analyzing the firm's forward P/S, an investor assesses market capitalization relative to expected revenue, which helps determine the extent to which the asset is overvalued given the absence of current sales and the high risks associated with the monetization of patents.

Pesaing langsung

Rasio rega marang prakiraan pendapatan Jazz Pharmaceuticals plc JAZZ|Cytokinetics Inc. - Rasio rega marang prakiraan pendapatan|PTCT - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Scholar Rock Inc.|CNTA: Multiplikator Forward P/S|Prakiraan rega marang pendapatan dyne-tx.com DYN|Multiplikator forward rega marang pendapatan EWTX|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Rapport Therapeutics Inc RAPP|Multiplikator Forward P/S ALMS|Multiplikator forward rega marang pendapatan Zevra Corp ZVRA|Multiplikator Forward P/S CTNM (Contineum Therapeutics, Inc.)|Multiplikator Forward P/S larimartx.com LRMR|TRDA - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan PTHS|medicinova.com (MNOV) - Rasio rega marang prakiraan pendapatan|Serina Pharma - Rega forward marang dodolan|BTAI (BioXcel Therapeutics) - Multiplikator Forward P/S|ProMIS (PMN) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S APUS|Multiplikator forward rega marang pendapatan aeonbiopharma.com AEON|Rasio rega marang prakiraan pendapatan NLS Pharmaceutics NLSP|Bionomics Ltd. (BNOX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|HUGE - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan RETA (reatapharma.com)